Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer

Host: Ryan Quigley <br> <p>Triple-negative breast cancer (TNBC) remains one of the hardest subtypes to treat, with limited options and high relapse rates—so identifying new therapeutic targets is critical. In this <i>AudioAbstract, </i>Ryan Quigley spotlights research presented at the San Antonio Breast Cancer Symposium that implicates ribosome biogenesis as a key vulnerability. Tune in to learn how this approach could inform the next generation of TNBC therapies. </p>